Business Context and Reporting Period
Company: Organogenesis Holdings Inc.
Filing Type: Form 8-K (Current Report)
Report Date: August 9, 2023
Reporting Period: Fiscal Second Quarter ended June 30, 2023
This filing serves as a notification that the Company announced its financial results for the second quarter of 2023 via a press release. The detailed financial data is contained within the press release attached as Exhibit 99.1, which is incorporated by reference but explicitly stated as "furnished" rather than "filed" for liability purposes under Section 18 of the Exchange Act.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being available in the attached press release (Exhibit 99.1) but are not present in the body of this 8-K filing.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the announcement of results for the quarter ended June 30, 2023.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release containing the results but does not include the text of the commentary, guidance, or outlook within this document.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text. The document notes that the information in the attached press release is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Investor Verification Checklist
- Review the attached press release (Exhibit 99.1) for specific Q2 2023 revenue, net income, and cash flow figures.
- Verify the Company's liquidity position and debt levels as detailed in the referenced press release.
- Check for any forward-looking guidance or updated financial outlook provided in the August 9, 2023 announcement.
- Confirm the status of the "furnished" versus "filed" designation for the press release to understand liability limitations.